Colorectal Cancer Clinical Trial
Official title:
Prognostic Factors Influencing the Recurrence Rate and Survival of Patients With Colorectal Cancer: a Single Institution Experience
Verified date | March 2024 |
Source | Zagazig University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
over the past decade colon cancer has emerged as the second most deadly and the third most common type of cancer in the world with increasing incidence in Egypt due to life style and diet change. some research showed relation between colon cancer recurrence and advanced tumor staging. To investigators knowledge, this is the first time to be done in Zagazig University. Data was collected from records in a retrospective cohort study
Status | Completed |
Enrollment | 200 |
Est. completion date | December 2022 |
Est. primary completion date | December 2022 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult patients with newly diagnosed colorectal cancer - Age > 18 years old - recurrent cases of colorectal cancer Exclusion Criteria: - Pediartric patient less than 18 yr - In operable or metastatic cancer colon - No other malignancies |
Country | Name | City | State |
---|---|---|---|
Egypt | Zagazig University Hospitals | Zagazig |
Lead Sponsor | Collaborator |
---|---|
Zagazig University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | age | age of patients was obtained from medical records | through study completion, an average of 5 years | |
Primary | sex | sex of patients was obtained from medical records | through study completion, an average of 5 years | |
Primary | medical disease | co-existing medical disease was obtained from medical records | through study completion, an average of 5 years | |
Primary | previous surgery | previous surgical history was obtained from medical records | through study completion, an average of 5 years | |
Primary | CEA | value of carcino-embryonic antigen was recorded | through study completion, an average of 5 years | |
Primary | tumor grade | tumor grade after resection from pathology report recorded | through study completion, an average of 5 years | |
Primary | tumor site | tumor site recorded from operative findings | through study completion, an average of 5 years | |
Primary | tumor size | tumor size was measured by length x width in cm from records | through study completion, an average of 5 years | |
Primary | surgical margins of resected tumor | safety margins were assessed from pathological examination under microscopy and recorded in pathology reports, it can be free surgical margins ( no tumor cells) or positive surgical margins( presence of tumor cells) | through study completion, an average of 5 years | |
Primary | neoadjuvant therapy | history of neoadjuvant therapy before surgery from records obtained | through study completion, an average of 5 years | |
Primary | adjuvant therapy | history of adjuvant therapy post operative obtained from records | through study completion, an average of 5 years | |
Primary | diet | diet and dietary life style from history | through study completion, an average of 5 years | |
Primary | occupation | occupation of the patient at time of surgery and if it was changed | through study completion, an average of 5 years | |
Primary | family history | history taking of family history of cancer disease | through study completion, an average of 5 years | |
Primary | type of surgery(laparoscopic or open) | type of operation was laparoscopic or open surgery obtained from records | through study completion, an average of 5 years | |
Primary | soiling by during surgery | by history from records if there was soiling of the field by tumor cells | through study completion, an average of 5 years | |
Primary | hand sewen or stappled anastmosis | if there was bowel re-anastmosis after surgery, it was done using a stappler or hand sewing sutures. this was obtained from operative data in patient records | through study completion, an average of 5 years | |
Primary | post operative complications | from records; if there were post operative complication like fecal fistula | through study completion, an average of 5 years | |
Primary | site of recurrence | site of tumor recurrence was detected | through study completion, an average of 5 years | |
Primary | type of resected tumor | type of tumor was recorded from pathology reports | through study completion, an average of 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |